2014 Fiscal Year Final Research Report
Enhancement of anti-tumor immune responses by EGFR-TKIs (EGFR- tyrosin kinase inhibitors)
| Project/Area Number |
25830122
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | がん免疫療法 / 肺癌 |
|---|
| Outline of Final Research Achievements |
In this study, we evaluated the enhancement of anti-tumor immune responses by EGFR-tyrosine kinase inhibitor (TKI) in non-small cell lung carcinoma cell (NSCLC). Human NSCLC with mutated EGFR produced immunosuppressive cytokines and suppressed human DC function, which were restored by EGFR-TKI pretreatment of NSCLC. EGFR-TKI directly enhanced human DC function in an EGFR-independent manner. Moreover, in vivo administration of EGFR-TKI augmented tumor antigen-specific T cell induction and enhanced anti-tumor effects of immunotherapies. These results indicate that EGFR-TKIs may have an activity to enhance antitumor immune responses for NSCLC by targeting both cancer cells and DC, and combined use of EGFR-TKIs may augment the therapeutic effects of current immunotherapies.
|
| Free Research Field |
腫瘍免疫学
|
